Anteris Technologies Global Corp. — AGM Information 2007

Nov 12, 2007

==> picture [143 x 73] intentionally omitted <==

==> picture [143 x 74] intentionally omitted <==

==> picture [142 x 62] intentionally omitted <==

==> picture [143 x 62] intentionally omitted <==

==> picture [143 x 71] intentionally omitted <==

Annual General Meeting 2007

bioMD Limited Innovative Biomedical Devices and Technologies

==> picture [142 x 71] intentionally omitted <==

==> picture [50 x 45] intentionally omitted <==

Annual General Meeting 2007

AGENDA

WELCOME

Mr Robert Scott, Chairman of the Board

CHAIRMAN’S ADDRESS

RESOLUTIONS

1) Adopt the Remuneration Report for the Year Ended 30 June 2007 2) Re-election of Director, Mr Robert Scott

Annual General Meeting 2007

Company Highlights

3 Pre-clinical Trials successfully completed;

Ethics Approval received for a Phase II Human Clinical Trial of cardiovascular patches treated with the ADAPT Tissue Processing Technology;

Presentation at “The Society for Heart Valve Disease” 4[th ] Biennial Meeting in New York by Celxcel’s Chief Scientific Officer, Dr Leon Neethling.

Annual General Meeting 2007

ADAPT[®]

Pre-Clinical Studies 2006/07

ADAPT Treated Bovine Pericardial Tissue Patches in the Jugular Position

ADAPT Treated Kangaroo and Bovine Pericardial Tissue Patches and Kangaroo Carotid Artery Grafts Comparison of ADAPT Treated Bovine Pericardial Patch with two commercially available biomaterial patches.

Annual General Meeting 2007

PHASE II HUMAN CLINICAL TRIAL

CARDIOCEL Bioimplant Tissue Patch (ADAPT treated bovine pericardium)

Trial to be conducted at Universitas Hospital, Bloemfontein, South Africa

==> picture [245 x 179] intentionally omitted <==

Ethics Committee approval granted - University of the Free State, Bloemfontein

Annual General Meeting 2007

PHASE II HUMAN CLINICAL TRIAL

CARDIOCEL – a bioimplant tissue using ADAPT Tissue Processing Technology for the repair of heart defects in openheart surgery, e.g. “hole in the heart” procedures 50 patient trial CARDIOCEL bioimplants will be implanted over a 12 month period Post-operative 12 month follow up for each patient

Annual General Meeting 2007

PATCH MANUFACTURING

Agreement signed with The Ray & Bill Dobney Cell Tissue Therapies WA manufacturing unit at Royal Perth Hospital

==> picture [317 x 207] intentionally omitted <==

Annual General Meeting 2007

PATCH MANUFACTURING

==> picture [106 x 47] intentionally omitted <==

PHASE II HUMAN CLINICAL TRIAL

BIOCOMPATIBILITY TESTING Manufacture of patches for independent testing, giving FDA approved certificate

Annual General Meeting 2007

THE WAY FORWARD

We are here

Animal Trials

Human Trials

Manufacturing facility

==> picture [98 x 31] intentionally omitted <==

----- Start of picture text -----

TGA / CE/ FDA
Approval
----- End of picture text -----

Commercialisation Sign Licence / Co-development

Annual General Meeting 2007

Presentation at SHVD

“Enhanced Durability and Biocompatibility of Decellularised Bovine Pericardium, Crosslinked with an Ultra Low Concentration Monomeric Aldehyde and treated with ADAPT®”

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

==> picture [136 x 16] intentionally omitted <==

Presentation at “The Society for Heart Valve Disease” 4th Biennial Meeting in New York; Presented by Celxcel’s Chief Scientific Officer,

==> picture [136 x 16] intentionally omitted <==

==> picture [135 x 7] intentionally omitted <==

Annual General Meeting 2007

ADAPT[®]

Emerging Technologies

Minimally invasive (keyhole) heart valve replacements Patent Foramen Ovale’s (PFO) Heart Defects Using Matrix to deliver “growth factors” and “stem cells”

Annual General Meeting 2007

==> picture [382 x 381] intentionally omitted <==

ADAPT[®]

ADAPT Tissue Processing Technology can be used to process bioimplants that can be used in 5 surgical specialties

Annual General Meeting 2007

ADAPT[®]

==> picture [535 x 318] intentionally omitted <==

----- Start of picture text -----

USA Soft Tissue Market, by type, (US$865M) 2007
Ventral Hernia Staple Line
Repair
Vaginal Sling
Rotator Cuff
Reinforcement
Inguinal Hernia
Repair
Dural Repair Pelvic Floor
Source: Millennium Research Group
----- End of picture text -----

Annual General Meeting 2007

Global Medical Device Companies

Multi-specialty 1[st ] Tier

• Johnson & Johnson

• Boston Scientific

• Bard / Davol

• Covidien

2[nd ] Tier

Annual General Meeting 2007

CSIRO Collaborative Research Agreement

Research completed in the Materials Robustness Phase (Stage II Phase 2) Research commenced in the revised statement of work for Stage III

Provisional patent application lodged in

==> picture [213 x 390] intentionally omitted <==

Annual General Meeting 2007

Intellectual Property

CSIRO Catheter Material

1 Patent application in progress

ADAPT Tissue Processing Technology 1 Patent granted

16 Patents pending

5 Patent applications

Annual General Meeting 2007

The Year Ahead

Global Partnering for the ADAPT Tissue Processing Technology

Co-product development Co-marketing Licensing

TGA Certification for ADAPT[® ] Tissue Processing Technology

Annual General Meeting 2007

Quality Assurance

==> picture [86 x 153] intentionally omitted <==

bioMD has Quality Assurance Accreditation to AS9001:2000

Our QA System also meets the requirements of AS13485 which specifically covers the manufacture of Medical Devices.

Annual General Meeting 2007

bioMD at a glance…

==> picture [92 x 92] intentionally omitted <==

Listed on Australian Stock Exchange - 24 March 2004 Market Capitalisation @ 31/10/07 Fully Paid Ordinary Shares Top 50 Shareholders Group Cash position @ 31/10/07 ADAPT[®] Advanced Tissue Group Average Cash Burn Anti-calcification

$10.12 million 84.3 million 73.6%

$1.9 million $70,000 per month